[go: up one dir, main page]

NO20073155L - Farmasoytisk preparat - Google Patents

Farmasoytisk preparat

Info

Publication number
NO20073155L
NO20073155L NO20073155A NO20073155A NO20073155L NO 20073155 L NO20073155 L NO 20073155L NO 20073155 A NO20073155 A NO 20073155A NO 20073155 A NO20073155 A NO 20073155A NO 20073155 L NO20073155 L NO 20073155L
Authority
NO
Norway
Prior art keywords
cell surface
surface molecules
antibodies against
autoimmune diseases
diseases
Prior art date
Application number
NO20073155A
Other languages
English (en)
Other versions
NO331064B1 (no
Inventor
Takuya Tamatani
Katsunari Tezuka
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26403281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073155(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20073155L publication Critical patent/NO20073155L/no
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of NO331064B1 publication Critical patent/NO331064B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Record Carriers (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20073155A 1997-02-27 2007-06-20 Farmasoytisk preparat NO331064B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP6229097 1997-02-27
JP06221798A JP3521382B2 (ja) 1997-02-27 1998-02-26 細胞間接着及びシグナル伝達を媒介する細胞表面分子
PCT/JP1998/000837 WO1998038216A1 (fr) 1997-02-27 1998-02-27 Molecule de surface cellulaire induisant l'adhesion cellulaire et la transmission de signaux

Publications (2)

Publication Number Publication Date
NO20073155L true NO20073155L (no) 1999-10-27
NO331064B1 NO331064B1 (no) 2011-09-26

Family

ID=26403281

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19994146A NO327500B1 (no) 1997-02-27 1999-08-26 Polypeptid som utgjor et celleoverflatemolekyl, polypeptidfragment, gen, vektor, transformant, fusjonspolypeptid, homodimert molekyl, farmasoytisk preparat, antistoff, eller del av dette, hybridom, transgen mus samt knockout-mus.
NO20073155A NO331064B1 (no) 1997-02-27 2007-06-20 Farmasoytisk preparat
NO20092369A NO20092369L (no) 1997-02-27 2009-06-18 Polypeptid som utgjor et celleoverflatemolekyl, polypeptidfragment, gen, vektor, transformant, fusjonspolypeptid, homodimert molekyl, farmasoytisk preparat, antistoff eller del av dette, hybridom og transgen mus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19994146A NO327500B1 (no) 1997-02-27 1999-08-26 Polypeptid som utgjor et celleoverflatemolekyl, polypeptidfragment, gen, vektor, transformant, fusjonspolypeptid, homodimert molekyl, farmasoytisk preparat, antistoff, eller del av dette, hybridom, transgen mus samt knockout-mus.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20092369A NO20092369L (no) 1997-02-27 2009-06-18 Polypeptid som utgjor et celleoverflatemolekyl, polypeptidfragment, gen, vektor, transformant, fusjonspolypeptid, homodimert molekyl, farmasoytisk preparat, antistoff eller del av dette, hybridom og transgen mus

Country Status (19)

Country Link
US (10) US7030225B1 (no)
EP (2) EP0984023B9 (no)
JP (1) JP3521382B2 (no)
KR (1) KR100349388B1 (no)
CN (3) CN100400546C (no)
AT (1) ATE360645T1 (no)
AU (1) AU732378B2 (no)
BR (1) BR9807788B1 (no)
CA (1) CA2282727C (no)
DE (1) DE69837658T2 (no)
DK (1) DK0984023T3 (no)
ES (1) ES2285763T3 (no)
ID (1) ID23386A (no)
IL (3) IL131584A0 (no)
NO (3) NO327500B1 (no)
NZ (1) NZ337425A (no)
PT (1) PT984023E (no)
SI (1) SI0984023T1 (no)
WO (1) WO1998038216A1 (no)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
AU752433B2 (en) * 1997-09-23 2002-09-19 Bundesrepublik Deutschland letzvertreten durch Den Direktor des Robert-Koch-Instituts Costimulating T-cell polypeptide, monoclonal antibodies, their preparation and use
EP1119253A4 (en) * 1998-10-07 2005-12-21 Millennium Pharm Inc NEW SPECIFIC MOLECULES OF Th2 AND USES THEREOF
US7708993B2 (en) 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
IL144635A0 (en) * 1999-02-03 2002-05-23 Amgen Inc Novel polypeptides involved in immune response
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
AU6615500A (en) 1999-07-28 2001-02-19 Genetics Institute Inc. Preventing immune-mediated abortion by inhibiting costimulation
MXPA02001877A (es) 1999-08-23 2002-08-20 Dana Farber Cancer Inst Inc Pd-1, un receptor para b7-4, y usos del mismo.
JP3871503B2 (ja) * 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
ATE366814T1 (de) 1999-09-21 2007-08-15 Genetics Inst Llc Gl50 moleküle, sowie verwendungen derselben
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7312044B2 (en) 2003-03-07 2007-12-25 The Trustees Of Columbia University In The City Of New York Type 1 ryanodine receptor-based methods
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
JP3543966B2 (ja) * 2000-05-18 2004-07-21 日本たばこ産業株式会社 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
CN1309735C (zh) * 2000-05-26 2007-04-11 布里斯托尔-迈尔斯斯奎布公司 可溶性ctla4突变体分子及其应用
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
RU2295537C2 (ru) * 2000-10-20 2007-03-20 Тугаи Сейяку Кабусики Кайся Модифицированное агонистическое антитело
WO2002074803A2 (en) * 2001-01-16 2002-09-26 Bayer Aktiengesellschaft Regulation of human icos v protein
WO2002059294A1 (en) 2001-01-26 2002-08-01 Commonwealth Scientific And Industrial Research O Rganisation Methods and means for producing efficient silencing construct using recombinational cloning
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
AU2002338272B2 (en) 2001-04-02 2007-10-11 Dana-Farber Cancer Institute, Inc. PD-1, a receptor for B7-4, and uses therefor
AU2002302851A1 (en) * 2001-06-21 2003-01-08 Isis Innovations Limited Atopy
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US8318905B2 (en) 2004-04-23 2012-11-27 Richard Kroczek Antibodies for depletion of ICOS-positive cells in vivo
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2007141971A1 (ja) 2006-06-07 2007-12-13 National University Corporation, Tokyo Medical And Dental University 筋特異的チロシンキナーゼの活性を制御するポリペプチドをコードするdna
WO2008149794A1 (ja) 2007-05-30 2008-12-11 Hoya Corporation 眼内レンズ挿入器具
WO2008149795A1 (ja) 2007-05-30 2008-12-11 Hoya Corporation 眼内レンズ挿入器具
US8502739B2 (en) * 2007-06-22 2013-08-06 Nokia Corporation Antenna arrangement
JP5086713B2 (ja) 2007-07-11 2012-11-28 Hoya株式会社 眼内レンズ挿入器具
EP2221065B1 (en) 2007-11-26 2016-12-28 Japan Science and Technology Agency Therapeutic or prophylactic agent, detection method and detection agent for metabolic syndrome, and method for screening of candidate compound for therapeutic agent for metabolic syndrome
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
US20120114595A1 (en) 2009-07-16 2012-05-10 Otsuka Chemical Co., Ltd. Sugar chain-added ailim extracellular domain and method for producing same
US20130042873A1 (en) 2010-03-09 2013-02-21 Klaus Bechgaard Contraceptive device
ES2550060T3 (es) 2010-03-12 2015-11-04 Abbvie Biotherapeutics Inc. Proteínas de CTLA4 y sus usos
WO2014089113A1 (en) 2012-12-03 2014-06-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
CA2913490A1 (en) 2013-06-06 2014-12-11 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of cancer using pd-l1 isoforms
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
ITUB20151014A1 (it) * 2015-05-27 2016-11-27 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
US12060394B2 (en) * 2016-04-28 2024-08-13 The Trustees Of Dartmouth College Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗pd-l1抗体
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
CN117736325A (zh) 2016-08-09 2024-03-22 科马布有限公司 分离抗体及其应用
US11932679B2 (en) 2016-09-02 2024-03-19 Keio University Agent for restoring visual function or agent for preventing deterioration in visual function
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3502140A1 (en) * 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
WO2019183551A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
EP3977132A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Cell localization signature and combination therapy
WO2021049634A1 (ja) 2019-09-13 2021-03-18 株式会社レストアビジョン キメラロドプシンをコードする核酸コンストラクト
US11771741B2 (en) 2019-09-13 2023-10-03 Restore Vision Inc. Nucleic acid construct that encodes chimeric rhodopsin
CA3154999A1 (en) 2019-10-28 2021-05-06 Catherine Eugenie Chaillan Huntington Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
JP2023530109A (ja) 2020-06-11 2023-07-13 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
CN116438199A (zh) 2020-08-31 2023-07-14 百时美施贵宝公司 细胞定位特征和免疫疗法
CN116648265A (zh) 2020-09-17 2023-08-25 锐视维公司 用于治疗或预防与内质网应激或全反式视黄醛相关的疾病、障碍或症状、或者用于保护视网膜厚度、或者用于抑制视网膜厚度的萎缩或萎缩进展的组合物
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
ES3023507T3 (en) 2020-12-28 2025-06-02 Bristol Myers Squibb Co Antibody compositions and methods of use thereof
EP4267172A1 (en) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
WO2022243378A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
US20250206775A1 (en) 2022-03-18 2025-06-26 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
KR20250022071A (ko) 2022-06-02 2025-02-14 브리스톨-마이어스 스큅 컴퍼니 항체 조성물 및 이의 이용 방법
JPWO2024048688A1 (no) 2022-08-31 2024-03-07
EP4583999A1 (en) 2022-09-09 2025-07-16 Bristol-Myers Squibb Company Methods of separating chelator
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US182667A (en) * 1876-09-26 Improvement in flue-stoppers
US164697A (en) * 1875-06-22 Improvement in cloth-steaming machines
US177191A (en) * 1876-05-09 Improvement in lamps
NZ218336A (en) * 1985-12-09 1991-08-27 Kirin Amgen Inc Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
SE8801537D0 (sv) * 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5504126A (en) * 1991-11-07 1996-04-02 Safas Corporation Mineral-like coating and methods of using same
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
JP4864175B2 (ja) 1996-01-23 2012-02-01 ジェネンテック, インコーポレイテッド 発作に関する抗―cd18抗体
US5914112A (en) 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
NZ334714A (en) 1996-09-18 2000-08-25 Zetesis Spa Liver proteins as agents against autoimmune diseases
EP1878748A2 (en) 1996-11-08 2008-01-16 Biogen Idec Inc. Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 costimulatory antigens
AU4145597A (en) 1997-02-20 1998-09-09 Cedars-Sinai Medical Center Ulcerative colitis panca secretory vesicle antigen and methods of using sa me
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
DE69836729T2 (de) 1997-04-07 2007-12-13 Genentech, Inc., South San Francisco Anti-vefg antibodies
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
AU752433B2 (en) 1997-09-23 2002-09-19 Bundesrepublik Deutschland letzvertreten durch Den Direktor des Robert-Koch-Instituts Costimulating T-cell polypeptide, monoclonal antibodies, their preparation and use
JPH11228442A (ja) 1998-02-09 1999-08-24 Cypros Pharmaceut Corp 臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用
JP2000154151A (ja) 1998-09-14 2000-06-06 Kyo Jo 免疫抑制剤
EP1119253A4 (en) 1998-10-07 2005-12-21 Millennium Pharm Inc NEW SPECIFIC MOLECULES OF Th2 AND USES THEREOF
IL144635A0 (en) 1999-02-03 2002-05-23 Amgen Inc Novel polypeptides involved in immune response
CN1377279A (zh) 1999-05-06 2002-10-30 遗传研究所有限公司 可溶性共同刺激分子增强免疫应答的用途
AU6615500A (en) 1999-07-28 2001-02-19 Genetics Institute Inc. Preventing immune-mediated abortion by inhibiting costimulation
WO2001012658A2 (en) 1999-08-11 2001-02-22 Isis Innovations Limited Human icos ligand and application thereof
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
EP1212343A4 (en) 1999-09-03 2004-11-03 Human Genome Sciences Inc 52 HUMAN SECRETED PROTEINS
ATE366814T1 (de) 1999-09-21 2007-08-15 Genetics Inst Llc Gl50 moleküle, sowie verwendungen derselben
CA2386641A1 (en) 1999-10-29 2001-05-10 Human Genome Sciences, Inc. 32 human secreted proteins
WO2001064704A1 (en) 2000-03-02 2001-09-07 Mayo Foundation For Medical Education And Research hB7-H2, A NOVEL CO-STIMULATORY MOLECULE
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
AU1796902A (en) 2000-11-28 2002-06-11 Amgen Inc Novel polypeptides involved in immune response
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
WO2004003544A1 (en) * 2002-06-26 2004-01-08 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of demyelinating inflammatory disorders

Also Published As

Publication number Publication date
IL131584A (en) 2010-06-30
US20030083472A1 (en) 2003-05-01
AU732378B2 (en) 2001-04-26
US20120003231A1 (en) 2012-01-05
CN1618811A (zh) 2005-05-25
US7247612B2 (en) 2007-07-24
ID23386A (id) 2000-04-20
US20040146506A1 (en) 2004-07-29
EP0984023B9 (en) 2008-04-16
ATE360645T1 (de) 2007-05-15
US8389690B2 (en) 2013-03-05
US20080248031A1 (en) 2008-10-09
US7196175B2 (en) 2007-03-27
NZ337425A (en) 2001-04-27
NO994146D0 (no) 1999-08-26
IL131584A0 (en) 2001-01-28
DE69837658T2 (de) 2007-12-27
SI0984023T1 (sl) 2007-08-31
US7294473B2 (en) 2007-11-13
CN100400546C (zh) 2008-07-09
CN1221569C (zh) 2005-10-05
WO1998038216A1 (fr) 1998-09-03
EP0984023A4 (en) 2001-10-31
EP1502920A2 (en) 2005-02-02
CA2282727C (en) 2009-06-16
US20040073012A1 (en) 2004-04-15
BR9807788A (pt) 2000-02-15
DE69837658D1 (de) 2007-06-06
NO327500B1 (no) 2009-07-20
NO20092369L (no) 1999-10-27
EP0984023A1 (en) 2000-03-08
CN1293190C (zh) 2007-01-03
US20040151669A1 (en) 2004-08-05
CA2282727A1 (en) 1998-09-03
US20040120945A1 (en) 2004-06-24
NO331064B1 (no) 2011-09-26
US7030225B1 (en) 2006-04-18
NO994146L (no) 1999-10-27
US7259147B2 (en) 2007-08-21
HK1079240A1 (en) 2006-03-31
CN1624115A (zh) 2005-06-08
PT984023E (pt) 2007-07-19
BR9807788B1 (pt) 2010-11-16
US7932358B2 (en) 2011-04-26
ES2285763T3 (es) 2007-11-16
KR100349388B1 (ko) 2002-08-22
EP1502920A3 (en) 2005-02-09
CN1253567A (zh) 2000-05-17
US7279560B2 (en) 2007-10-09
US20040229788A1 (en) 2004-11-18
IL206603A0 (en) 2011-07-31
KR20000075761A (ko) 2000-12-26
JP3521382B2 (ja) 2004-04-19
JPH1129599A (ja) 1999-02-02
AU6118598A (en) 1998-09-18
HK1026433A1 (en) 2000-12-15
EP0984023B1 (en) 2007-04-25
DK0984023T3 (da) 2007-07-09
EP1502920B1 (en) 2015-09-09
US20040151720A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
NO331064B1 (no) Farmasoytisk preparat
FI963101L (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
DE60334460D1 (de) Antikörper spezifisch für das tau-protein des zentralen nervensystems
DE69021456D1 (de) Monoklonale Antikörper gegen aktivierte endotheliale Zellen.
BR9710968A (pt) Antìgenos de célula b humana; reagentes correlatos
FR06C0024I2 (fr) Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4
DE69841102D1 (de) Monoklonaler antikörper gegen ein prion protein und dessen verwendung zum nachweis von prionen
WO2001012659A3 (en) Human dna sequences
DE69927268D1 (de) Spezifische antikörper enthaltende bindungsproteine die das nekrotische tumorzentrum binden und deren verwendung
DE69836438D1 (de) Substantiell reine histidin-gebundene protein polymerkonjugate
FI965030A7 (fi) Hiivassa ekspressoituneet N-terminaalisesti pidennetyt proteiinit
DE59609222D1 (de) Amperometrischer Biosensor
FI973055A0 (fi) Soluja yhdistelmä-DNA-adenovirusten tuottamiseksi
DK0904357T3 (da) Protein med phospholipase-aktivitet
WO1996009386A3 (en) Allelic variation of the serotonin 5ht2c receptor
FI950507L (fi) Määritysmenetelmä proteiinin määrittämiseksi biologisesta näytteestä
NO20000097L (no) Isolerte dendrittcellemembranproteingener
WO2001016184A3 (en) Diagnostic assay for type 2 heparin-induced thrombocytopenia
WO2001069247A3 (en) Methods of making and using microarrays of anti-ligands for the analysis of protein expression in cells
FR2773157B1 (fr) Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide
EA199800959A1 (ru) ПРИМЕНЕНИЕ ГЕНЕТИЧЕСКОЙ МОДИФИКАЦИИ В ГЕНЕ b3- СУБЪЕДИНИЦЫ ЧЕЛОВЕЧЕСКОГО G-ПРОТЕИНА ДЛЯ ДИАГНОСТИКИ ЗАБОЛЕВАНИЙ
AU3444499A (en) Monoclonal antibody 3-6-a specific to surface of dendritic cells among the peripheral blood leukocytes
DE69631624D1 (de) Antikörper gegen menschliches restrictin
WO2005062959A3 (en) Isolated t lymphocyte receptors specific for human autoantigens complexed with human mhc molecules and methods of making and using same
WO2006089422A8 (en) Protein and its use in diagnosing alzheimer's disease

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees